- Home
- MITQ vs APLM Comparison
MITQ vs APLM Comparison
Compare MITQ & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MITQ
- APLM
- Stock Information
- Founded
- MITQ N/A
- APLM 2016
- Country
- MITQ United States
- APLM United States
- Employees
- MITQ N/A
- APLM N/A
- Industry
- MITQ Telecommunications Equipment
- APLM Blank Checks
- Sector
- MITQ Telecommunications
- APLM Finance
- Exchange
- MITQ Nasdaq
- APLM Nasdaq
- Market Cap
- MITQ 7.6M
- APLM 6.8M
- IPO Year
- MITQ 2021
- APLM N/A
- Fundamental
- Price
- MITQ $0.75
- APLM $6.23
- Analyst Decision
- MITQ
- APLM
- Analyst Count
- MITQ 0
- APLM 0
- Target Price
- MITQ N/A
- APLM N/A
- AVG Volume (30 Days)
- MITQ 102.6K
- APLM 63.0K
- Earning Date
- MITQ 09-25-2025
- APLM 08-13-2025
- Dividend Yield
- MITQ N/A
- APLM N/A
- EPS Growth
- MITQ N/A
- APLM N/A
- EPS
- MITQ N/A
- APLM N/A
- Revenue
- MITQ $18,613,000.00
- APLM $198,000.00
- Revenue This Year
- MITQ N/A
- APLM $415.15
- Revenue Next Year
- MITQ N/A
- APLM N/A
- P/E Ratio
- MITQ N/A
- APLM N/A
- Revenue Growth
- MITQ N/A
- APLM N/A
- 52 Week Low
- MITQ $0.50
- APLM $4.47
- 52 Week High
- MITQ $1.55
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- MITQ 58.78
- APLM 50.06
- Support Level
- MITQ $0.74
- APLM $4.73
- Resistance Level
- MITQ $0.76
- APLM $8.18
- Average True Range (ATR)
- MITQ 0.05
- APLM 0.74
- MACD
- MITQ 0.00
- APLM 0.02
- Stochastic Oscillator
- MITQ 68.80
- APLM 43.43
About MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.